Restenosis of the Coronary Arteries: Past, Present, Future Directions.

Restenosis is a pathologic response to vascular injury, characterized by neointimal hyperplasia and progressive narrowing of a stented vessel segment. Although advances in stent design have led to a dramatic reduction in the incidence of restenosis, it continues to represent the most common cause of target lesion failure following percutaneous coronary intervention. Efforts to maximize restenosis prevention, through careful consideration of modifiable risk factors and an individualized approach, are critical, as restenosis, once established, can be particularly difficult to treat. Novel approaches are on the horizon that have the potential to alter the natural history of this stubborn disease.

[1]  J. Kallen,et al.  Chemical modification of rapamycin: the discovery of SDZ RAD. , 1998, Transplantation proceedings.

[2]  M. Leon,et al.  Treatment of in-stent restenosis with excimer laser coronary angioplasty: mechanisms and results compared with PTCA alone. , 1997, Circulation.

[3]  P. Serruys,et al.  Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. , 2006, JAMA.

[4]  S. Silber,et al.  Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery Lesions , 2003, Circulation.

[5]  R. Virmani,et al.  Endothelial cell recovery between comparator polymer-based drug-eluting stents. , 2008, Journal of the American College of Cardiology.

[6]  M. Kimura,et al.  Morphological differences of tissue characteristics between early, late, and very late restenosis lesions after first generation drug-eluting stent implantation: an optical coherence tomography study. , 2013, European heart journal cardiovascular Imaging.

[7]  A. Ionescu,et al.  Bare metal stent restenosis is not a benign clinical entity. , 2006, American heart journal.

[8]  K. Kent,et al.  Intravascular brachytherapy versus drug-eluting stents for the treatment of patients with drug-eluting stent restenosis. , 2006, The American journal of cardiology.

[9]  J. Isner,et al.  Regional differences in the distribution of the proteoglycans biglycan and decorin in the extracellular matrix of atherosclerotic and restenotic human coronary arteries. , 1994, The American journal of pathology.

[10]  P. Teirstein,et al.  A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. , 1994, The New England journal of medicine.

[11]  P. D. de Feyter,et al.  Periprocedural quantitative coronary angiography after Palmaz-Schatz stent implantation predicts the restenosis rate at six months: results of a meta-analysis of the BElgian NEtherlands Stent study (BENESTENT) I, BENESTENT II Pilot, BENESTENT II and MUSIC trials. Multicenter Ultrasound Stent In Coro , 1999, Journal of the American College of Cardiology.

[12]  Hae-Young Lee,et al.  Does "late catch-up" exist in drug-eluting stents: insights from a serial quantitative coronary angiography analysis of sirolimus versus paclitaxel-eluting stents. , 2010, American heart journal.

[13]  Patrick W Serruys,et al.  Coronary Restenosis After Sirolimus‐Eluting Stent Implantation: Morphological Description and Mechanistic Analysis From a Consecutive Series of Cases , 2003, Circulation.

[14]  P. Serruys,et al.  Reference chart derived from post-stent-implantation intravascular ultrasound predictors of 6-month expected restenosis on quantitative coronary angiography. , 1999, Circulation.

[15]  J. Douglas,et al.  Restenosis after percutaneous transluminal coronary angioplasty: the Emory University Hospital experience. , 1987, The American journal of cardiology.

[16]  C. Macaya,et al.  A randomized comparison of repeat stenting with balloon angioplasty in patients with in-stent restenosis. , 2003, Journal of the American College of Cardiology.

[17]  P. Serruys,et al.  Post–Sirolimus-Eluting Stent Restenosis Treated With Repeat Percutaneous Intervention: Late Angiographic and Clinical Outcomes , 2004, Circulation.

[18]  D. Carrié,et al.  Everolimus-eluting stent for the treatment of bare metal in-stent restenosis: clinical and angiographic outcomes at nine-month follow-up of XERES (Xience Evaluation in bare metal stent REStenosis) trial. , 2014, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[19]  Seung‐Jung Park,et al.  Mechanisms of In-Stent Restenosis After Drug-Eluting Stent Implantation: Intravascular Ultrasound Analysis , 2011, Circulation. Cardiovascular interventions.

[20]  Jeffrey W Moses,et al.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.

[21]  A. Colombo,et al.  Drug-eluting stent restenosis the pattern predicts the outcome. , 2006, Journal of the American College of Cardiology.

[22]  A. Kastrati,et al.  Intracoronary Stenting and Angiographic Results: Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO) Trial , 2001, Circulation.

[23]  P. Fitzgerald,et al.  Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. , 2008, JAMA.

[24]  P. Serruys,et al.  Influence of Coronary Vessel Size on Renarrowing Process and Late Angiographic Outcome After Successful Balloon Angioplast , 1994, Circulation.

[25]  A. Kastrati,et al.  Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. , 2010, Journal of the American College of Cardiology.

[26]  C. Heldin,et al.  Different Effects of High and Low Shear Stress on Platelet-Derived Growth Factor Isoform Release by Endothelial Cells: Consequences for Smooth Muscle Cell Migration , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[27]  M. Fishbein,et al.  A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. , 1991, Journal of the American College of Cardiology.

[28]  A. Sato,et al.  Mechanisms explaining the late "catch-up" phenomenon after sirolimus-eluting stent implantation. , 2014, International journal of cardiology.

[29]  Gregg W. Stone,et al.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease , 2004 .

[30]  K. Messmer,et al.  Platelet-endothelial cell interactions during ischemia/reperfusion : The role of P-selectin , 1998 .

[31]  F. Eberli,et al.  Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. , 2005, The New England journal of medicine.

[32]  C. V. van Mieghem,et al.  Final 5-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice: The COMPARE Trial (A Trial of Everolimus-Eluting Stents and Paclitaxel Stents for Coronary Revascularization in Daily Practice). , 2015, JACC. Cardiovascular interventions.

[33]  M. Hadamitzky,et al.  Predictive factors of restenosis after coronary stent placement. , 1997, Journal of the American College of Cardiology.

[34]  B. Marchandise,et al.  Long-term outcome of patients with asymptomatic restenosis after percutaneous transluminal coronary angioplasty. , 1993, The American journal of cardiology.

[35]  S. Silber,et al.  Rotational Atherectomy Does Not Reduce Recurrent In-Stent Restenosis: Results of the Angioplasty Versus Rotational Atherectomy for Treatment of Diffuse In-Stent Restenosis Trial (ARTIST) , 2002, Circulation.

[36]  Mary E. Russell,et al.  TAXUS I: Six- and Twelve-Month Results From a Randomized, Double-Blind Trial on a Slow-Release Paclitaxel-Eluting Stent for De Novo Coronary Lesions , 2003, Circulation.

[37]  P. Serruys,et al.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. , 2002, The New England journal of medicine.

[38]  P. Fitzgerald,et al.  Randomized, Double-Blind, Multicenter Study of the Endeavor Zotarolimus-Eluting Phosphorylcholine-Encapsulated Stent for Treatment of Native Coronary Artery Lesions: Clinical and Angiographic Results of the ENDEAVOR II Trial , 2006, Circulation.

[39]  Gregg W Stone,et al.  A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial. , 2011, Journal of the American College of Cardiology.

[40]  U. Heinzmann,et al.  A Crucial Role of Glycoprotein VI for Platelet Recruitment to the Injured Arterial Wall In Vivo , 2003, The Journal of experimental medicine.

[41]  A. Baumbach,et al.  Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. , 2000, Journal of the American College of Cardiology.

[42]  S. Silber,et al.  Cutting balloon versus conventional balloon angioplasty for the treatment of in-stent restenosis: results of the restenosis cutting balloon evaluation trial (RESCUT). , 2004, Journal of the American College of Cardiology.

[43]  G. Stone,et al.  Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. , 1999, Circulation.

[44]  G. Stone,et al.  Non–Polymer-Based Paclitaxel-Coated Coronary Stents for the Treatment of Patients With De Novo Coronary Lesions: Angiographic Follow-Up of the DELIVER Clinical Trial , 2004, Circulation.

[45]  Patrick W Serruys,et al.  Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. , 2007, Journal of the American College of Cardiology.

[46]  Yiannis S. Chatzizisis,et al.  Role of endothelial shear stress in stent restenosis and thrombosis: pathophysiologic mechanisms and implications for clinical translation. , 2012, Journal of the American College of Cardiology.

[47]  Seung‐Jung Park,et al.  Optical Coherence Tomographic Analysis of In-Stent Neoatherosclerosis After Drug–Eluting Stent Implantation , 2011, Circulation.

[48]  M. S. Williams,et al.  Stent and artery geometry determine intimal thickening independent of arterial injury. , 2000, Circulation.

[49]  E. Edelman,et al.  Endovascular stent design dictates experimental restenosis and thrombosis. , 1995, Circulation.

[50]  W. J. van der Giessen,et al.  Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries , 2000, Heart.

[51]  Kurt Ulm,et al.  Sirolimus-Eluting Stents vs Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease: Meta-analysis of Randomized Trials , 2005 .

[52]  G. Mintz,et al.  Relation of stent design and stent surface material to subsequent in-stent intimal hyperplasia in coronary arteries determined by intravascular ultrasound. , 2002, The American journal of cardiology.

[53]  G. Biondi-Zoccai,et al.  Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V®) , 2008, Vascular health and risk management.

[54]  P. Serruys,et al.  Late coronary occlusion after intracoronary brachytherapy. , 1999, Circulation.

[55]  R. Waksman,et al.  Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel Meeting on the Endeavor Zotarolimus-Eluting Coronary Stent , 2008, Circulation.

[56]  H. Garcia-Garcia,et al.  Study of restenosis in drug eluting stents: new insights from greyscale intravascular ultrasound and virtual histology. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[57]  B. Gersh Sirolimus-Eluting Stent or Paclitaxel-Eluting Stent vs Balloon Angioplasty for Prevention of Recurrences in Patients With Coronary In-Stent Restenosis: A Randomized Controlled Trial , 2006 .

[58]  Soo-Jin Kang,et al.  In-stent neoatherosclerosis: a final common pathway of late stent failure. , 2012, Journal of the American College of Cardiology.

[59]  M. Takano,et al.  Optical coherence tomography analysis for restenosis of drug-eluting stents. , 2011, International journal of cardiology.

[60]  R. Guidoin,et al.  The benefits of fluoropassivation of polyester arterial prostheses as observed in a canine model. , 1994, ASAIO journal.

[61]  Gregg W Stone,et al.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. , 2004, The New England journal of medicine.

[62]  P. Teirstein,et al.  Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. , 2006, JAMA.

[63]  P. Libby,et al.  Production of platelet-derived growth factor-like mitogen by smooth-muscle cells from human atheroma. , 1988, The New England journal of medicine.

[64]  R. Falotico,et al.  Polymers for drug eluting stents. , 2010, Current pharmaceutical design.

[65]  W Rutsch,et al.  A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. , 1994, The New England journal of medicine.

[66]  M. Hadamitzky,et al.  Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. , 1998, Journal of the American College of Cardiology.

[67]  D Schwartz,et al.  A Cascade Model for Restenosis: A Special Case of Atherosclerosis Progression , 1992, Circulation.

[68]  D. Baim,et al.  Defining coronary restenosis. Newer clinical and angiographic paradigms. , 1993, Circulation.

[69]  C. Di Mario,et al.  Preliminary Observations Regarding Angiographic Pattern of Restenosis After Rapamycin-Eluting Stent Implantation , 2003, Circulation.

[70]  F. Fernández‐Avilés,et al.  Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients: The Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial , 2005, Circulation.

[71]  A. Colombo,et al.  Long-term outcomes after the percutaneous treatment of drug-eluting stent restenosis. , 2011, JACC. Cardiovascular interventions.

[72]  Robyn L McClelland,et al.  Clinical and Angiographic Predictors of Restenosis After Percutaneous Coronary Intervention: Insights From the Prevention of Restenosis With Tranilast and Its Outcomes (PRESTO) Trial , 2004, Circulation.

[73]  P. Tsao,et al.  Stent-Based Delivery of Sirolimus Reduces Neointimal Formation in a Porcine Coronary Model , 2001, Circulation.

[74]  J. Gunn,et al.  Phosphorylcholine-coated stents in porcine coronary arteries: in vivo assessment of biocompatibility. , 2001, The Journal of invasive cardiology.

[75]  P. Stella,et al.  Serial morphological and functional assessment of drug-eluting balloon for in-stent restenotic lesions: mechanisms of action evaluated with angiography, optical coherence tomography, and fractional flow reserve. , 2013, JACC. Cardiovascular interventions.

[76]  Theodore A Bass,et al.  Impact of stent deployment procedural factors on long-term effectiveness and safety of sirolimus-eluting stents (final results of the multicenter prospective STLLR trial). , 2008, The American journal of cardiology.

[77]  M. Hadamitzky,et al.  Influence of lesion length on restenosis after coronary stent placement. , 1999, The American journal of cardiology.

[78]  S. Silber,et al.  Rotational Atherectomy Does Not Reduce Recurrent In-Stent Restenosis Results of the Angioplasty Versus Rotational Atherectomy for Treatment of Diffuse In-Stent Restenosis Trial (ARTIST) , 2002 .

[79]  A. Rollins,et al.  Intracoronary optical coherence tomography: a comprehensive review clinical and research applications. , 2009, JACC. Cardiovascular interventions.

[80]  Hong Wang,et al.  Five-year follow up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial , 2009 .

[81]  R. Whitbourn,et al.  The next-generation Endeavor Resolute stent: 4-month clinical and angiographic results from the Endeavor Resolute first-in-man trial. , 2007, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[82]  P. Buttner,et al.  A meta-analysis of randomised controlled trials assessing drug-eluting stents and vascular brachytherapy in the treatment of coronary artery in-stent restenosis. , 2008, International journal of cardiology.

[83]  H. Schieffer,et al.  Factors affecting the restenosis rate after percutaneous transluminal coronary angioplasty. , 1994, Thrombosis research.

[84]  G. Knapp,et al.  Drug-eluting balloon angioplasty for in-stent restenosis: a systematic review and meta-analysis of randomised controlled trials , 2013, Heart.

[85]  H Yokoi,et al.  Three-year follow-up after implantation of metallic coronary-artery stents. , 1996, The New England journal of medicine.

[86]  R E Vlietstra,et al.  Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. , 1992, Journal of the American College of Cardiology.

[87]  P. Serruys,et al.  Clinical and Angiographic Factors Associated With Asymptomatic Restenosis After Percutaneous Coronary Intervention , 2001, Circulation.

[88]  Lack of Neointimal Proliferation After Implantation of Sirolimus-Coated Stents in Human Coronary Arteries: A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study , 2001 .

[89]  P. Serruys,et al.  Sustained Suppression of Neointimal Proliferation by Sirolimus-Eluting Stents , 2002 .

[90]  M. Kimura,et al.  A comparison of clinical presentations, angiographic patterns and outcomes of in-stent restenosis between bare metal stents and drug eluting stents. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[91]  P. Serruys,et al.  Long-term luminal renarrowing after successful elective coronary angioplasty of total occlusions. A quantitative angiographic analysis. , 1995, Circulation.

[92]  K. Kent,et al.  Five-Year Follow-Up After Intracoronary Gamma Radiation Therapy for In-Stent Restenosis , 2004, Circulation.

[93]  W. Siegenthaler,et al.  Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. , 1979, The New England journal of medicine.

[94]  M. Pfisterer,et al.  A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. , 2007, Journal of the American College of Cardiology.

[95]  M. Leon,et al.  The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. , 1998, Journal of the American College of Cardiology.

[96]  J. Wilcox,et al.  Identification of a potential role for the adventitia in vascular lesion formation after balloon overstretch injury of porcine coronary arteries. , 1996, Circulation.

[97]  Emo Centro Patterns of restenosis after drug-eluting stent implantation: Insights from a contemporary and comparative analysis of sirolimus-and paclitaxel-eluting stents , 2007 .

[98]  M. Savage,et al.  Restenosis after coronary angioplasty: a multivariate statistical model to relate lesion and procedure variables to restenosis. The M-HEART Investigators. , 1991, Journal of the American College of Cardiology.

[99]  J. Wilcox,et al.  Novel high-throughput polymer biocompatibility screening designed for SAR (structure-activity relationship): application for evaluating polymer coatings for cardiovascular drug-eluting stents. , 2009, Combinatorial chemistry & high throughput screening.

[100]  Yung-wu Chen,et al.  Zotarolimus, a Novel Sirolimus Analogue With Potent Anti-proliferative Activity on Coronary Smooth Muscle Cells and Reduced Potential for Systemic Immunosuppression , 2007, Journal of cardiovascular pharmacology.

[101]  A. Lewis,et al.  Analysis of a phosphorylcholine-based polymer coating on a coronary stent pre- and post-implantation. , 2002, Biomaterials.

[102]  I. Penn,et al.  Intravascular ultrasound-guided optimized stent deployment. Immediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries Study (MUSIC Study) , 1998, European heart journal.

[103]  Jörg Hausleiter,et al.  Randomized Trial of a Nonpolymer-Based Rapamycin-Eluting Stent Versus a Polymer-Based Paclitaxel-Eluting Stent for the Reduction of Late Lumen Loss , 2006, Circulation.

[104]  M. Schreier,et al.  SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. , 1997, Transplantation.

[105]  M. Joner,et al.  Polymer coatings and delayed arterial healing following drug-eluting stent implantation. , 2009, Minerva cardioangiologica.

[106]  P Serruys,et al.  Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group. , 1998, The New England journal of medicine.

[107]  J. Barry,et al.  The Taxus drug-eluting stent: a new paradigm in controlled drug delivery. , 2006, Advanced drug delivery reviews.

[108]  Benno J. Rensing,et al.  Sustained Suppression of Neointimal Proliferation by Sirolimus-Eluting Stents: One-Year Angiographic and Intravascular Ultrasound Follow-Up , 2001, Circulation.

[109]  G. Stone,et al.  Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. , 2006, JAMA.

[110]  M. Niemelä,et al.  Randomized Study on Simple Versus Complex Stenting of Coronary Artery Bifurcation Lesions: The Nordic Bifurcation Study , 2006, Circulation.

[111]  C. Macaya,et al.  Value of the American College of Cardiology/American Heart Association angiographic classification of coronary lesion morphology in patients with in-stent restenosis. Insights from the Restenosis Intra-stent Balloon angioplasty versus elective Stenting (RIBS) randomized trial. , 2006, American heart journal.

[112]  A. Pichard,et al.  Safety and efficacy of everolimus-eluting stents for bare-metal in-stent restenosis. , 2015, Cardiovascular revascularization medicine : including molecular interventions.

[113]  F. Welt,et al.  Inflammation and Restenosis in the Stent Era , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[114]  G. Papandreou,et al.  Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent , 2002, Coronary artery disease.